Health X Platform DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.85×	0.61×	0.69×	0.11×	2.66×
	0.41×	0.04×	3.12×	−14.96×	0.72×
	−5.0%	−4.5%	−5.6%	−0.3%	−5.0%
	1.38×	1.38×	1.05×	1.17×	0.84×
	1.22×	1.22×	1.13×	1.15×	1.21×
	−3.0%	−0.2%	−14.2%	0.6%	−9.8%
	0.2%	0.2%	−10.9%	0.9%	−7.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HEALTHX₹279.20

Health X Platform Limited

· Pharma & Health

₹ CrorePeersSURAKSHA KRSNAA NEPHROPLUS 3BBLACKBIOMcap ₹888 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	2.66	0.11	0.69	0.61	0.85
Interest Burden (Pretax/EBIT) ×	0.72	-14.96	3.12	0.04	0.41
EBIT Margin %	-5.02	-0.27	-5.57	-4.45	-5.03
Asset Turnover ×	0.84	1.17	1.05	1.38	1.38
Financial Leverage (Assets/Equity) ×	1.21	1.15	1.13	1.22	1.22
ROE (5-step product, year-end total equity) %	-9.75	0.57	-14.23	-0.19	-3.00
ROE (owners' profit / average owners' equity) %	-7.59	0.89	-10.92	0.18	0.18

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.